Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.77 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.63 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26775744 | 0.92 | HDAC1 (0.90) | HDAC1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL30739586 | 0.90 | HDAC1 (0.75) | HDAC1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL29996129 | 0.88 | HDAC1 (0.63) | HDAC1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL26416452 | 0.88 | HDAC1 (0.63) | HDAC1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL15551664 | 0.87 | HDAC1 (1.00) | HDAC1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL19392337 | 0.84 | NPC1 (0.71) | HDAC1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL30369924 | 0.83 | HDAC1 (0.77) | HDAC1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL6588596 | 0.83 | HDAC1 (0.77) | HDAC1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL20577364 | 0.83 | HDAC1 (0.66) | HDAC1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL682876 | 0.83 | PTGS1 (0.61) | HDAC1NPC1RAB9ASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081933-B1 | PYRAZOLOPYRIMIDINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| US-20090286779-A1 | PYRAZOLOPYRIMIDINES AS LIPID KINASE INHIBITORS | NOVARTIS AG | 2009-11-19 | — | — | US | disclosed |
| EP-2081933-A1 | PYRAZOLOPYRIMIDINES AS P13K LIPID KINASE INHIBITORS | Novartis Ag (CH) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008037477-A1 | PYRAZOLOPYRIMIDINES AS P13K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286779-A1 | PYRAZOLOPYRIMIDINES AS LIPID KINASE INHIBITORS | ATR, ATM, CHEK1 | HDAC1 285/4885NPC1 1299/4885RAB9A 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.